AR122499A1 - Anticuerpo humanizado anti-receptor de igf-1 - Google Patents

Anticuerpo humanizado anti-receptor de igf-1

Info

Publication number
AR122499A1
AR122499A1 ARP210101492A ARP210101492A AR122499A1 AR 122499 A1 AR122499 A1 AR 122499A1 AR P210101492 A ARP210101492 A AR P210101492A AR P210101492 A ARP210101492 A AR P210101492A AR 122499 A1 AR122499 A1 AR 122499A1
Authority
AR
Argentina
Prior art keywords
antibody
igf
humanized anti
receptor
igf11
Prior art date
Application number
ARP210101492A
Other languages
English (en)
Inventor
Hiroaki Matsukawa
Hiroshi Eguchi
Naoko Namiki
Akira Tanokura
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR122499A1 publication Critical patent/AR122499A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se presenta un anticuerpo humanizado anti-receptor de IGF-1 que puede aumentar la masa muscular sin inducir síntomas hipoglucémicos por medio de un receptor de IGF-1 humano. El anticuerpo comprende: regiones determinantes de la complementariedad de cadena pesada y de cadena liviana (CDRs) cada una de las cuales es derivada de anticuerpo parental de ratón IGF11-16; y regiones de marco de cadena pesada y de cadena liviana (FRs) cada una de las cuales es derivada de un anticuerpo humano, donde por lo menos una de las CDRs contiene una sustitución de por lo menos un residuo aminoácido con respecto a la correspondiente CDR del anticuerpo parental de ratón IGF11-16.
ARP210101492A 2020-06-02 2021-06-01 Anticuerpo humanizado anti-receptor de igf-1 AR122499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020096344 2020-06-02

Publications (1)

Publication Number Publication Date
AR122499A1 true AR122499A1 (es) 2022-09-14

Family

ID=78831168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101492A AR122499A1 (es) 2020-06-02 2021-06-01 Anticuerpo humanizado anti-receptor de igf-1

Country Status (14)

Country Link
EP (1) EP4159860A1 (es)
JP (2) JPWO2021246413A1 (es)
KR (1) KR20230006006A (es)
CN (1) CN115605594A (es)
AR (1) AR122499A1 (es)
AU (1) AU2021282629A1 (es)
BR (1) BR112022022030A2 (es)
CA (1) CA3176119A1 (es)
CL (1) CL2022003399A1 (es)
CO (1) CO2022017026A2 (es)
IL (1) IL296519A (es)
MX (1) MX2022015133A (es)
TW (1) TW202210513A (es)
WO (1) WO2021246413A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114561337B (zh) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 一种提高HepG2细胞克隆形成率的单克隆增强培养基和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2841575T (lt) * 2012-04-27 2019-10-10 Millennium Pharmaceuticals, Inc. Antikūno molekulės, nukreiptos prieš gcc, ir jų panaudojimas nustatant jautrumą į gcc nukreiptai terapijai
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
IL270971B1 (en) * 2017-05-30 2024-02-01 Teijin Pharma Ltd Antibody against the 1-IGF receptor
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
AU2019217207A1 (en) * 2018-02-12 2020-08-27 Diabetes-Free, Inc. Improved antagonistic anti-human CD40 monoclonal antibodies
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
AR117673A1 (es) * 2018-12-03 2021-08-25 Teijin Pharma Ltd Anticuerpo humanizado anti-receptor de igf-i

Also Published As

Publication number Publication date
AU2021282629A1 (en) 2022-12-01
EP4159860A1 (en) 2023-04-05
JP2024054410A (ja) 2024-04-16
CL2022003399A1 (es) 2023-08-11
CA3176119A1 (en) 2021-12-09
TW202210513A (zh) 2022-03-16
WO2021246413A1 (ja) 2021-12-09
MX2022015133A (es) 2023-01-11
KR20230006006A (ko) 2023-01-10
JPWO2021246413A1 (es) 2021-12-09
CN115605594A (zh) 2023-01-13
IL296519A (en) 2022-11-01
CO2022017026A2 (es) 2022-12-09
BR112022022030A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
Zohar et al. Dissecting antibody-mediated protection against SARS-CoV-2
Hoffmann-Vold et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
Mattia et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study
CL2022003399A1 (es) Anticuerpo humanizado anti- receptor de igf-1
Samad et al. Incidence of diabetes mellitus and factors associated with its development in HIV-positive patients over the age of 50
Hyle et al. The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan Africa: a systematic review
Cannon et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice
Chou et al. Screening for HIV: systematic review to update the 2005 US Preventive Services Task Force recommendation
Scharf et al. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody
Parcesepe et al. Mental health and HIV: research priorities related to the implementation and scale up of ‘treat all’in sub-Saharan Africa
Puertas et al. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report
Choi et al. Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa
Essajee et al. Transient acetylcholine receptor-related myasthenia gravis, post multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19 infection
Del Romero et al. Absence of transmission from HIV-infected individuals with HAART to their heterosexual serodiscordant partners
Nduati et al. Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination
Batista et al. Initial suboptimal CD4 reconstitution with antiretroviral therapy despite full viral suppression in a cohort of HIV-infected patients in Senegal
Madeddu et al. Renal toxicity in HIV-infected patients receiving HAART including tenofovir
Lum et al. HIV testing and ART initiation in people who inject drugs and are placed on methadone in Kachin State, Myanmar
CL2021001446A1 (es) Anticuerpo humanizado anti-receptor de igf-i
Lenox-Smith et al. Treatment and outcomes for patients with depression who are partial responders to SSRI treatment: post-hoc analysis findings from the FINDER European observational study
Follmann et al. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop
Li et al. One step closer to universal influenza epitopes
Joshi et al. Thyroid function disorders in HIV/AIDS patients in Nepal
Bibi et al. Frequency of syphilis in female sex workers at red light area of Hyderabad, Pakistan.
Judd et al. Post‐licensing safety of fosamprenavir in HIV‐infected children in Europe